Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03176173 · ClinicalTrials.gov registry record · NA
Radical RADiotherapy and Immunotherapy for Metastatic CAncer of the Lung (RRADICAL)
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 45
- Enrollment target
NCT03176173: Completed NA study, sponsored by Stanford University.
NCT03176173 is a NA study that has completed, run by Stanford University. The registered enrollment target is 45 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03176173, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
Study Summary
This phase II trial studies how well radical-dose image guided radiation therapy works in treating patients with non-small cell lung cancer that has spread to other places in the body who are undergoing immunotherapy. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving radical-dose image guided radiation therapy to patients with non-small cell lung cancer may help to improve response to immunotherapy anti-cancer treatment.
Primary Outcome
Defined as percentage of participants without disease progression or death at 24 weeks from date of study entry, assessed per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Complete Response (CR): Disappearance of all target lesions Partial Response (PR): ≥30% decrease in the sum of the longest diameter of target lesions Overall Response (OR): CR + PR
Interventions
- RADIATION Image-guided Radiation Therapy
- DRUG Immunotherapy (physician's choice for standard of care immunotherapy)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2017-06-28 |
| Est. Completion | 2025-01-31 |
| Phase | NA |
What the finished NCT03176173 record still lists
NCT03176173 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Image-guided Radiation Therapy is the first listed.
NCT03176173 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03176173 about?
NCT03176173 is a clinical study titled "Radical RADiotherapy and Immunotherapy for Metastatic CAncer of the Lung (RRADICAL)". This phase II trial studies how well radical-dose image guided radiation therapy works in treating patients with non-small cell lung cancer that has spread to other places in the body who are undergoing immunotherapy. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. G...
What is the current status of trial NCT03176173?
This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2017-06-28. Estimated completion is 2025-01-31.
What interventions are being tested in trial NCT03176173?
The interventions under investigation include: Image-guided Radiation Therapy (RADIATION), Immunotherapy (physician's choice for standard of care immunotherapy) (DRUG).
Who is sponsoring clinical trial NCT03176173?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03176173's enrollment target sits among peer trials
45 1411th of 2000 higher than 578 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI